دورية أكاديمية
أعرض في EDS

Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics-An Observational Study.

التفاصيل البيبلوغرافية
العنوان: Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics-An Observational Study.
المؤلفون: Miron AA; Facultatea de Medicină, Universitatea Transilvania din Brașov, Bulevardul Eroilor nr. 29, 500036 Brașov, Romania.; Spitalul Clinic de Psihiatrie și Neurologie Brașov, Str. Prundului nr. 7-9, 500123 Brașov, Romania., Petric PS; Facultatea de Medicină, Universitatea Transilvania din Brașov, Bulevardul Eroilor nr. 29, 500036 Brașov, Romania.; Spitalul Clinic de Psihiatrie și Neurologie Brașov, Str. Prundului nr. 7-9, 500123 Brașov, Romania., Teodorescu A; Facultatea de Medicină, Universitatea Transilvania din Brașov, Bulevardul Eroilor nr. 29, 500036 Brașov, Romania.; Spitalul Clinic de Psihiatrie și Neurologie Brașov, Str. Prundului nr. 7-9, 500123 Brașov, Romania., Ifteni P; Facultatea de Medicină, Universitatea Transilvania din Brașov, Bulevardul Eroilor nr. 29, 500036 Brașov, Romania.; Spitalul Clinic de Psihiatrie și Neurologie Brașov, Str. Prundului nr. 7-9, 500123 Brașov, Romania., Chele G; Facultatea de Medicină, Universitatea de Medicină si Farmacie, Grigore T. Popa' Iași, Str. Universității nr. 16, 700115 Iași, Romania.; Institutul de Psihiatrie 'Socola' Iași, Şoseaua Bucium nr. 36, 700282 Iași, Romania., Szalontay AS; Facultatea de Medicină, Universitatea de Medicină si Farmacie, Grigore T. Popa' Iași, Str. Universității nr. 16, 700115 Iași, Romania.; Institutul de Psihiatrie 'Socola' Iași, Şoseaua Bucium nr. 36, 700282 Iași, Romania.
المصدر: Brain sciences [Brain Sci] 2023 Jan 20; Vol. 13 (2). Date of Electronic Publication: 2023 Jan 20.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101598646 Publication Model: Electronic Cited Medium: Print ISSN: 2076-3425 (Print) Linking ISSN: 20763425 NLM ISO Abbreviation: Brain Sci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Schizophrenia is a chronic, invalidating, and polymorphic disease, characterized by relapses and remission periods. The main treatment option in schizophrenia are antipsychotics, administered as an oral or as a long-acting injectable (LAI) formulation. Although international guidelines rarely recommend it, mood stabilizers (MS) and/or benzodiazepines (BZD) are frequently prescribed as adjunctive therapy in schizophrenia patients for various reasons. This is an observational, cross-sectional study including stabilized schizophrenia patients. A total of 315 patients were enrolled. Of these, 77 patients (24.44%) were stabilized on LAIs and 238 (75.56%) patients on oral antipsychotics (OAP). Eighty-four patients (26.66%) had concomitant treatment with MS and 119 patients (37.77%) had concomitant benzodiazepine treatment. No statistical significance was observed in MS or BZD use between LAIs and OAPs. In total, 136 patients (43.17%) were stabilized on antipsychotic monotherapy. Our study shows that the long-term use of benzodiazepines and mood stabilizers remains elevated among stabilized schizophrenia patients, regardless of the antipsychotic formulation (oral or LAI). Patients receiving second-generation LAI antipsychotics (SGA-LAI) seem to be more likely to be stabilized on monotherapy compared to those receiving oral antipsychotics. Further randomized controlled trials are necessary in order to clarify the benefits of the current drug polypharmacy trends.
References: Can J Psychiatry. 2007 Jul;52(7):457-63. (PMID: 17688010)
Int Clin Psychopharmacol. 1995 Jan;9 Suppl 5:5-9. (PMID: 7622834)
Adv Ther. 2022 Sep;39(9):3933-3956. (PMID: 35844007)
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005962. (PMID: 17054266)
Eur Neuropsychopharmacol. 2013 Sep;23(9):1023-33. (PMID: 23602690)
Psychiatr Serv. 2022 May;73(5):492-500. (PMID: 34587788)
Clin Geriatr Med. 2012 May;28(2):287-300. (PMID: 22500544)
Medicine (Baltimore). 2016 Jan;95(4):e2475. (PMID: 26825886)
J Clin Psychiatry. 2005;66 Suppl 2:9-13. (PMID: 15762814)
Am J Psychiatry. 2010 Jun;167(6):686-93. (PMID: 20360319)
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1065-70. (PMID: 15610918)
Psychiatr Serv. 2000 May;51(5):634-8. (PMID: 10783182)
Am J Psychiatry. 2020 Apr 1;177(4):342-353. (PMID: 31838873)
J Med Econ. 2013;16(2):231-9. (PMID: 23163287)
Acta Psychiatr Scand. 2023 Mar;147(3):257-266. (PMID: 36065482)
Acta Psychiatr Scand Suppl. 1994;382:6-10. (PMID: 7916528)
Tidsskr Nor Laegeforen. 2005 Jun 30;125(13):1809-12. (PMID: 16012547)
Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):361-375. (PMID: 30466208)
Psychiatr Danub. 2017 Sep;29(Suppl 3):345-348. (PMID: 28953788)
Healthcare (Basel). 2022 Jul 07;10(7):. (PMID: 35885792)
Curr Opin Psychiatry. 2013 Mar;26(2):208-13. (PMID: 23318662)
Psychiatr Danub. 2017 Sep;29(Suppl 3):349-352. (PMID: 28953789)
Neuropsychopharmacology. 2003 Jan;28(1):182-92. (PMID: 12496955)
Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2):3-7. (PMID: 16001094)
Am J Psychiatry. 1977 Feb;134(2):138-43. (PMID: 835733)
J Clin Psychopharmacol. 2010 Oct;30(5):531-40. (PMID: 20814320)
Obstet Gynecol. 2022 Sep 1;140(3):408-411. (PMID: 35926210)
Schizophr Res. 2018 Jul;197:274-280. (PMID: 29274734)
Eur J Clin Pharmacol. 2020 May;76(5):711-718. (PMID: 31940085)
Ther Adv Psychopharmacol. 2022 Aug 23;12:20451253221110016. (PMID: 36051503)
Hum Psychopharmacol. 2020 Nov;35(6):1-7. (PMID: 32738085)
Neuropsychiatr Dis Treat. 2018 Jun 08;14:1463-1474. (PMID: 29922062)
Ther Adv Psychopharmacol. 2018 Jun 22;8(11):287-301. (PMID: 30344996)
Pharmgenomics Pers Med. 2016 Nov 07;9:117-129. (PMID: 27853387)
Schizophr Bull. 2015 Nov;41(6):1397-402. (PMID: 25841041)
PLoS One. 2021 Sep 10;16(9):e0257129. (PMID: 34506552)
CNS Drugs. 2021 Nov;35(11):1189-1205. (PMID: 34636025)
Front Pharmacol. 2022 Jun 13;13:860713. (PMID: 35770081)
Int J Neuropsychopharmacol. 2020 Feb 1;23(2):125-131. (PMID: 31867671)
CNS Drugs. 2015;29(10):819-32. (PMID: 26482261)
Drugs. 2021 Jul;81(11):1273-1284. (PMID: 34196945)
Cochrane Database Syst Rev. 2015 Oct 28;(10):CD003834. (PMID: 26509923)
Cochrane Database Syst Rev. 2012 Nov 14;11:CD006391. (PMID: 23152236)
J Pers Med. 2022 Mar 11;12(3):. (PMID: 35330441)
CNS Drugs. 2008;22(1):49-68; discussion 69-72. (PMID: 18072814)
J Clin Psychiatry. 2016;77(suppl 3):1-24. (PMID: 27732772)
Pharmacotherapy. 1996 Nov-Dec;16(6 Pt 2):148S-151S; discussion 166S-168S. (PMID: 8947998)
Lancet Psychiatry. 2021 May;8(5):387-404. (PMID: 33862018)
Nat Rev Dis Primers. 2015 Nov 12;1:15067. (PMID: 27189524)
Curr Top Behav Neurosci. 2017;34:141-159. (PMID: 26695165)
Eur Psychiatry. 2018 Aug;52:85-94. (PMID: 29734130)
J Clin Psychiatry. 2016 May;77(5):661-7. (PMID: 27249075)
Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56. (PMID: 15000267)
Cochrane Database Syst Rev. 2014 May 02;(5):CD001258. (PMID: 24789267)
Pharmacol Rev. 2013 Jan 08;65(1):105-42. (PMID: 23300133)
Cochrane Database Syst Rev. 2016 Nov 24;11:CD004028. (PMID: 27884042)
Patient Prefer Adherence. 2017 Mar 23;11:619-629. (PMID: 28356723)
J Clin Psychopharmacol. 2022 Jan-Feb 01;42(1):37-42. (PMID: 34928559)
J Clin Psychol. 2021 Oct;77(10):2137-2146. (PMID: 34212382)
Psychiatry Res. 2008 Jan 15;157(1-3):251-4. (PMID: 17916385)
J Psychopharmacol. 2015 Feb;29(2):212-23. (PMID: 25049261)
JAMA Psychiatry. 2019 May 1;76(5):499-507. (PMID: 30785608)
Psychiatr Q. 2022 Jun;93(2):627-635. (PMID: 35235126)
Front Psychiatry. 2021 Dec 07;12:767756. (PMID: 34950069)
Psychiatry Clin Neurosci. 2015 Aug;69(8):440-7. (PMID: 25601291)
Basic Clin Pharmacol Toxicol. 2020 Mar;126(3):183-192. (PMID: 31908124)
فهرسة مساهمة: Keywords: antipsychotics; benzodiazepines; mood stabilizers; schizophrenia
تواريخ الأحداث: Date Created: 20230225 Latest Revision: 20230228
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9953951
DOI: 10.3390/brainsci13020173
PMID: 36831716
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-3425
DOI:10.3390/brainsci13020173